National Data on Prevalence of Idiopathic Pulmonary Fibrosis and Antifibrotic Drug Use in Finnish Specialised Care

Overview

Journal BMJ Open Respir Res

Date 2022 Dec 26

PMID 36571594

Authors

Johanna Salonen

Minna Purokivi

Ulla Hodgson

Riitta Kaarteenaho

Affiliations

Soon will be listed here.

Abstract

Introduction: The previous data concerning the prevalence of idiopathic pulmonary fibrosis (IPF) and the frequency of antifibrotic drug use in Finland were based on research registries and medical records whereas nationwide data on the number of patients with IPF in specialised care and those on antifibrotic treatment have not been published.

Methods: We made an information request to the Finnish National Hospital Discharge Register (Hilmo) covering the whole population of Finland to find out the annual numbers of patients with IPF treated in specialised care in 2016-2021. The numbers of the patients initiating and using pirfenidone and nintedanib were requested from the Social Insurance Institution of Finland (Kela) for the same time period.

Results: The estimated prevalence of IPF in specialised care was 36.0 per 100 000 in 2021, having increased since 2016. The number of antifibrotic drug users and their proportion of outpatients with IPF had also risen during the follow-up period. In 2021, 35% of the patients with IPF used pirfenidone or nintedanib. The number of inpatients treated in specialised care because of IPF had declined during 2016-2021.

Conclusions: The prevalence of IPF was higher than expected in Finnish specialised care and had increased during the 6-year follow-up time. The increase in the number of patients with IPF using antifibrotic drugs might have diminished the need for IPF-related hospitalisations.

Citing Articles

I-PreFer Study: A Questionnaire to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Treatment Options.

Hollmen M, Bromilow T, Smith A, Mealing S, Lewis D, Galvin L Patient Prefer Adherence. 2023; 17:1621-1639.

PMID: 37560148 PMC: 10408661. DOI: 10.2147/PPA.S408857.

Re-hospitalisation predicts poor prognosis after acute exacerbation of interstitial lung disease.

Salonen J, Jansa S, Vahanikkila H, Kaarteenaho R BMC Pulm Med. 2023; 23(1):236.

PMID: 37393286 PMC: 10315035. DOI: 10.1186/s12890-023-02534-0.

Virtual communication is commonly used in Finnish interstitial lung disease multidisciplinary meetings.

Salonen J, Nurmi H, Hodgson U, Hasala H, Kilpelainen M, Hollmen M Eur Clin Respir J. 2023; 10(1):2190210.

PMID: 36950471 PMC: 10026813. DOI: 10.1080/20018525.2023.2190210.

References

Mooney J, Reddy S, Chang E, Broder M, Gokhale S, Corral M . Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2021; 27(12):1724-1733. PMC: 10390936. DOI: 10.18553/jmcp.2021.27.12.1724. View

Hodgson U, Laitinen T, Tukiainen P . Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002; 57(4):338-42. PMC: 1746288. DOI: 10.1136/thorax.57.4.338. View

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Kondoh Y, Suda T, Hongo Y, Yoshida M, Hiroi S, Iwasaki K . Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respir Res. 2022; 23(1):24. PMC: 8822670. DOI: 10.1186/s12931-022-01938-6. View

Rajala K, Lehto J, Sutinen E, Kautiainen H, Myllarniemi M, Saarto T . Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life. BMC Pulm Med. 2018; 18(1):172. PMC: 6247520. DOI: 10.1186/s12890-018-0738-x. View

Skold C, Arnheim-Dahlstrom L, Bartley K, Janson C, Kirchgaessler K, Levine A . Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respir Med. 2019; 155:72-78. DOI: 10.1016/j.rmed.2019.06.001. View

Raghu G, Remy-Jardin M, Richeldi L, Thomson C, Inoue Y, Johkoh T . Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022; 205(9):e18-e47. PMC: 9851481. DOI: 10.1164/rccm.202202-0399ST. View

Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9. DOI: 10.1016/S0140-6736(11)60405-4. View

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

10.

Kolonics-Farkas A, Sterclova M, Mogulkoc N, Lewandowska K, Muller V, Hajkova M . Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries. Front Med (Lausanne). 2022; 8:729203. PMC: 8733326. DOI: 10.3389/fmed.2021.729203. View

11.

Lee H, Myong J, Kim H, Rhee C, Yoon H, Koo J . Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea. Int J Tuberc Lung Dis. 2016; 20(7):978-84. DOI: 10.5588/ijtld.16.0003. View

12.

Jo H, Glaspole I, Grainge C, Goh N, Hopkins P, Moodley Y . Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.01592-2016. View

13.

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M . Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020; 56(2). DOI: 10.1183/13993003.02279-2019. View

14.

Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R . Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med. 2015; 15:92. PMC: 4541726. DOI: 10.1186/s12890-015-0074-3. View

15.

Salonen J, Purokivi M, Bloigu R, Kaarteenaho R . Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir Res. 2020; 7(1). PMC: 7254157. DOI: 10.1136/bmjresp-2020-000563. View

16.

Collard H, Ryerson C, Corte T, Jenkins G, Kondoh Y, Lederer D . Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016; 194(3):265-75. DOI: 10.1164/rccm.201604-0801CI. View

17.

Snyder L, Mosher C, Holtze C, Lancaster L, Flaherty K, Noth I . Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. BMJ Open Respir Res. 2020; 7(1). PMC: 7337884. DOI: 10.1136/bmjresp-2020-000567. View

18.

Guenther A, Krauss E, Tello S, Wagner J, Paul B, Kuhn S . The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018; 19(1):141. PMC: 6064050. DOI: 10.1186/s12931-018-0845-5. View

19.

Maher T, Bendstrup E, Dron L, Langley J, Smith G, Khalid J . Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021; 22(1):197. PMC: 8261998. DOI: 10.1186/s12931-021-01791-z. View

20.

Kaunisto J, Salomaa E, Hodgson U, Kaarteenaho R, Myllarniemi M . Idiopathic pulmonary fibrosis--a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med. 2013; 13:53. PMC: 3765635. DOI: 10.1186/1471-2466-13-53. View